undamentalytics Newsletter
Sign in

Royalty Pharma plc income statement

In fiscal 2025, Royalty Pharma plc reported revenue of $2.38bn, up 5.1% on the year before, operating income of $1.56bn (a 65.6% margin) and net income of $771m, or $1.78 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue1,7951,8142,1222,2892,2372,3552,2642,3782,536
Research and development3938326200177522452239
General and administrative62103182183227250237573604
Operating income1,3642,6231,5951,4313071,4921,2921,5601,512
Interest expense280269157166188187226308361
Provision for credit losses−57−1,019156−13−194−22−100264
Income before tax1,5182,4611,7021,2412301,7001,3311,3241,350
Income tax000000000
Net income1,3782,349975620431,135859771815
Diluted EPS——$1.32$1.49$0.10$2.53$1.91$1.78$1.46
Diluted shares (average)——375m415m438m603m594m564m558m
EBITDA—————1,4921,2921,5631,517

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: AMRX vs RPRXLNTH vs RPRXPAHC vs RPRX

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Royalty Pharma plc's SEC filings (10-K and 10-Q), retrieved October 20, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Royalty Pharma plc.